Golden Green’s Corvus Pharmaceuticals CRVS Stock Holding History

Golden Green’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,539	Closed	-$70K	–	175
2020 Q4	$70K	Buy	+19,539	New	+$78.7K	0.07%	122

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Golden Green's CRVS Position: Q1 2021 in Review

Golden Green sold out of Corvus Pharmaceuticals (CRVS) in Q1 2021, closing a stake of 19,539 shares — an estimated $70K sold.

Golden Green first reported a position in CRVS in Q4 2020 and held it in 1 quarter. The position peaked at $70K in Q4 2020. 49 funds tracked by Wall St. Rank hold CRVS as of Q1 2021.

Golden Green reported no remaining Corvus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Golden Green sold 19,539 Corvus Pharmaceuticals shares in Q1 2021, an estimated $70K.
Golden Green first reported a position in Corvus Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Golden Green's Corvus Pharmaceuticals position peaked at $70K in Q4 2020.
49 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2021.

Based on Golden Green's 13F filing for Q1 2021, filed 13 Apr 2021.